RNTX - NASDAQ
Rein Therapeutics Inc.
$1.87
+0.53%Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.
At a Glance
Live Snapshotrntx
Research Development Expenses
Last Annual Value
11.03M
3-Year CAGR
750%
5-Year CAGR
297%
10-Year CAGR
99%
Rein Therapeutics Inc. Competitors Analysis of research-development-expenses
| Company | research-development-expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
 Rein Therapeutics Inc. NASDAQ:RNTX | 11.03M | 1303.3% | 265.1% | N/A | |
 Actinium Pharmaceuticals, Inc. AMEX:ATNM | 30.05M | -8.1% | 11.4% | 5.6% | |
 BioAtla, Inc. NASDAQ:BCAB | 63.09M | -15.3% | 1.6% | N/A | |
 HeartBeam, Inc. NASDAQ:BEAT | 13.45M | 25.5% | 121.0% | 4.9% | |
 Kezar Life Sciences, Inc. NASDAQ:KZR | 33.76M | -26.7% | -2.8% | 16.4% | |
 Mersana Therapeutics, Inc. NASDAQ:MRSN | 73.02M | -21.0% | -11.2% | 8.6% |
Rein Therapeutics Inc. Fair Value Envelope
Related Guides
Continue your RNTX research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.